BMS CA209-8HW

About this trial

A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

Patient Profile

Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC)

Where’s this trial being run?

St James’s Hospital, St Vincents University Hospital, and University Hospital Limerick

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: BMS CA209-8HW
Number: 18-08
Full Title:

A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer

Principal Investigator: Prof Ray McDermott (SVUH)/ Dr David Gallagher (SJH)/ Dr Osman Nemer (UHL)
Type: Industry Sponsored
Sponsor:

Bristol-Myers Squibb

Recruitment Started: Global: Q2 2019
Ireland: Q1 2021
Global Recruitment Target: 900
Ireland Recruitment Target: 10